Santa Monica, CA (PRWEB) June 08, 2011
Premiere Oncology, among the largest community-based Phase I clinical trial center in the United States, presented five abstracts at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Studies highlighted advances in experimental therapies for multiple tumor types.
Therapy advancements at Phase I clinical trials are critical in advancing cancer care and providing current patients with new avenues of treatment.
Abstract No. 7500
A phase 2 trial of Ganetespib (STA-9090), a potent, next-generation Hsp90 inhibitor, in patients with advanced non-small cell lung cancer. The study enrolled 73 patients, and promising activity was seen for tumors harboring wild-type EGFR and KRAS. At the conference there was particular excitement about the possibility of activity against ALK mutant tumors. A phase 2b/3 trial with docetaxel is underway.
Abstract No. 2614
A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. The trial found MEGF0444A is well tolerated and has good PK properties. Potential vascular targeting by MEGF0444A is suggested by changes in circulating progenitor cell levels and in vascular MR imaging (DCE-MRI). MEGF0444A is currently being investigated in combination with bevacizumab and chemotherapy in Phase 1 and 2 clinical trials; results in Abstract 2514.
Abstract No. 2514
A phase Ib dose escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. As a result of the trial, MEGF0444A has demonstrated favorable PK properties and is well tolerated in combination with bevacizumab and bevacizumab/paclitaxel. Study data supports a Phase 2 dose of 5 mg/kg q2 wks (flat dose equivalent, 400mg q2 or 600 mg q3 wks). Further studies of MEGF0444A in combination with chemotherapy and bevacizumab are planned.
Abstract No. 3076
First-in-human study with ARQ621, a novel inhibitor of Eg5: final results from a solid tumors cohort. As a result of the trial, ARQ621 appears well tolerated at the weekly dose of 280 mg/m2. The low rate of significant toxicities compared very favorably with other Eg5 inhibitors.
Abstract No. 3074
Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens. The trial found Amuvatinib is well tolerated in combination with five SOC regimens. The results support further investigation of Amuvatinib in combination with chemotherapy for treatment of small cell lung cancer and neuroendocrine tumors.